CTNM CONTINEUM THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CONTINEUM THERAPEUTICS INC reported revenue of n/a, net income of −$15.2M and diluted EPS of −$0.40; for the fiscal year ended December 2025 revenue was n/a.
CTNM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$68.1M, net income −$60.0M (margin n/a), EPS −$2.17
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$50.9M, net income −$42.3M (margin n/a), EPS −$2.18
- Fiscal year ended Dec 2023: revenue $50.0M, gross profit n/a, operating income $16.1M, net income $22.7M (margin 45.4%), EPS $0.08
CTNM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$15.2M, EPS −$0.40
- Quarter ended Mar 31, 2026: revenue n/a, net income −$14.5M, EPS −$0.39
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$15.2M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$12.8M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$16.0M, EPS −$0.62
- Quarter ended Mar 31, 2025: revenue n/a, net income −$16.0M, EPS −$0.62
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$14.6M, EPS n/a
- Quarter ended Sep 30, 2024: revenue $0, net income −$10.3M, EPS −$0.40
- Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$9.01M, EPS −$0.39
- Quarter ended Mar 31, 2024: revenue n/a, net income −$8.42M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$7.77M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $0, net income −$6.25M, EPS −$2.69
- Quarter ended Jun 30, 2023: revenue $50.0M, net income $41.6M, EPS $0.84
- Quarter ended Mar 31, 2023: revenue n/a, net income −$4.82M, EPS n/a
CTNM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$55.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$32.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $19.3M, share buybacks n/a
CTNM balance sheet
- Jun 30, 2026: cash $14.7M, total assets $250M, total liabilities $10.7M, shareholders' equity $240M
- Mar 31, 2026: cash $20.2M, total assets $261M, total liabilities $11.3M, shareholders' equity $250M
- Dec 31, 2025: cash $75.6M, total assets $277M, total liabilities $15.7M, shareholders' equity $261M
- Sep 30, 2025: cash $42.6M, total assets $191M, total liabilities $10.4M, shareholders' equity $180M
- Jun 30, 2025: cash $20.8M, total assets $183M, total liabilities $11.5M, shareholders' equity $171M
- Mar 31, 2025: cash $22.5M, total assets $198M, total liabilities $13.5M, shareholders' equity $185M
- Dec 31, 2024: cash $21.9M, total assets $213M, total liabilities $14.8M, shareholders' equity $198M
- Sep 30, 2024: cash $40.9M, total assets $216M, total liabilities $5.81M, shareholders' equity $210M
Is CTNM profitable?
No. CONTINEUM THERAPEUTICS INC lost $57.6M over the last four quarters.